Pharmaids Pharmaceuticals MD, chairman, board of directors and AGM
BSE: 524572Pharmaceuticals & BiotechnologySmall Cap
Share price at the BSE close on 23 Oct 2026. Previous close ₹28.29.
- Market capMarket capitalisation. Share price times the number of shares: what the whole company is worth at the day's price. The rank is by average market value over the six months to Jun 2026, among listed companies.
- ₹102 Cr2,774th largest listed
- P/EPrice to earnings, trailing. Market cap divided by the profit of the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly) that belongs to the company's own shareholders, after the share of the other owners of its subsidiaries: what investors pay for each rupee of a year's profit.
- Lossover the last 12 months
- P/BPrice to book. Market cap divided by the net worth that belongs to the company's own shareholders, its assets less everything it owes and less the other owners' share of its subsidiaries, on its latest balance sheet. The filing of 1 Jun 2026
- 2.1
- Dividend yieldDividend yield. Dividends paid per share in the twelve months to the day, as a percentage of the day's share price.
- Nonein the last 12 months
- ROEReturn on equity. Profit over the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly) that belongs to the company's own shareholders, as a percentage of their net worth, the money they have in the business. Net worth is the average of the latest balance sheet and the one a year before it. The filing of 12 Aug 2026
- −8.5%
- ROE without one-offsReturn on equity without one-off items. Core profit, the profit of the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly) that belongs to the company's own shareholders less one-off items (exceptional items and the result of businesses sold or closed), as a percentage of the same net worth as the return on equity. Shown where the one-off items move that profit by more than a tenth. The last twelve months' profit includes ₹6.70 crore of one-off items, the largest of them in the quarter to Jun 2026.
- −21.1%
- ROCEReturn on capital employed. Operating profit after depreciation (revenue less operating expenses and depreciation, without other income and one-off items) as a percentage of all the money the business runs on: the whole group's net worth, the other owners of its subsidiaries included, plus borrowings. Lease liabilities are not counted: the results filings do not state them. The profit is over the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly); net worth and borrowings are on the latest balance sheet. The filing of 12 Aug 2026
- −15.8%
- Debt to equityDebt to equity. Borrowings divided by the whole group's net worth, the other owners of its subsidiaries included: rupees borrowed for each rupee of equity in the business. Lease liabilities are not counted: the results filings do not state them. From the balance sheet at the end of Mar 2026. The filing of 1 Jun 2026
- 0.44
- Volume, BSEVolume. Shares traded on the last trading day.
- 1,482
Pharmaids Pharmaceuticals board of directors
At the end of the quarter to Jun 2026, as the company filed it; changes since are in its announcements.Their trades in its shares
- ChairpersonPATTAMADAI NATARAJASARMA VIJAY
- Company Secretary and Compliance OfficerPrasanna Subramanya Bhat
7 directors3 independent2 executive2 non-executive
- VENU MADHAVA KAPARTHYExecutive · joined May 2022 · reappointed May 2025 · 1 listed board · 2 committee seats
- MINI MANIKANTANExecutive · joined Jul 2022 · reappointed Jul 2025 · 1 listed board · 1 committee seat
- SHANKARAPPA NAGARAJA VINAYA BABUNon-executive · joined Jan 2024 · 1 listed board
- SHREEDHARA SHETTYNon-executive · joined Aug 2023 · 1 listed board
- PATTAMADAI NATARAJASARMA VIJAY · ChairpersonIndependent · joined Oct 2022 · reappointed Oct 2022 · 44 months as independent · 2 listed boards · 2 as independent · 3 committee seats, 2 as chair
- METHUKU NAGESHIndependent · joined Nov 2022 · reappointed Nov 2022 · 43 months as independent · 1 listed board · 1 as independent · 2 committee seats, 1 as chair
- YOGANANDA MOOLEMATHIndependent · joined Jan 2026 · reappointed Jan 2026 · 6 months as independent · 1 listed board · 1 as independent · 1 committee seat
An independent director has no business or family tie to the company, its promoters or its managers beyond the seat. Listed boards counts the boards of listed companies the director sits on, this one included, and "as independent" how many of those seats are independent ones. Committee seats are audit and stakeholder committee seats across those companies. Months as independent is filed for independent directors only, whose terms the rules cap. Disqualified is the company's own mark that a director may not serve under company law.
1 director who left
- MOPPERTHY SUDHEER, left 5 Jan 2026: Tenure Completion
Committees and meetings
Who sits on each, and how often they met.Board meeting notices and outcomes
Board
- 30 Jun 20267 of 7 present3 independent · 31 days in between
- 29 May 20266 of 7 present3 independent · 105 days in between
- 12 Feb 20267 of 7 present3 independent
Audit Committee
Chair PATTAMADAI NATARAJASARMA VIJAY
METHUKU NAGESH, VENU MADHAVA KAPARTHY, YOGANANDA MOOLEMATH
- 30 Jun 20264 of 4 present3 independent · 31 days in between
- 29 May 20264 of 4 present3 independent · 71 days in between
- 18 Mar 20264 of 4 present3 independent · 33 days in between
- 12 Feb 20264 of 4 present3 independent
Nomination and remuneration committee
Chair METHUKU NAGESH
PATTAMADAI NATARAJASARMA VIJAY, YOGANANDA MOOLEMATH
- 10 Jun 20263 of 3 present3 independent
Stakeholders Relationship Committee
Chair METHUKU NAGESH
VENU MADHAVA KAPARTHY, MINI MANIKANTAN
No meeting listed in the filing.
Meetings in the quarter filed and the one before it. The days in between are as the company files them, neither meeting's day counted; the rules allow at most 120. A quorum is the least number of members who must attend for the meeting to decide anything.
Statutory auditor
Named in the results for the quarter to Jun 2026.
- PPKG & CoPeer-review certificate valid to Jan 2029
1 earlier auditor
- PPKG&Co.Named in the filing for the quarter to Mar 2025
A statutory auditor checks the company's accounts and signs its results. Peer review is the accountants' institute's check of an audit firm's own work, which a listed company's auditor must hold a valid certificate of.
Pharmaids Pharmaceuticals AGM and shareholder votes
Each resolution, how the votes went, and how institutions voted apart from the promoters. A postal ballot is a vote by post or online, held without a meeting.Pharmaids Pharmaceuticals share news and announcements
Annual general meeting, 11 Sep 2026
8,866 shareholders on the register on 4 Sep 2026; present: 1 promoter and 83 others; votes counted by CS KASHINATH SAHU / KASHINATH SAHU & CO., PRACTICING COMPANY SECRETARIES.The company's voting result (opens in a new tab)
- Adoption of the Audited Financial Statements (Standalone and Consolidated) of the Company for the Financial Year ended 31st March' 2026 and the Reports of the Board of Directors and Auditors thereon.Ordinary100.00% for0.00% against
Against: promoters 0.00% · institutions 0.00% · other public 0.01%
Turnout: all 74.15% · promoters 99.93% · institutions 0.00% · other public 61.46%
- Appointment of Ms. Mini Manikantan (DIN: 09663184) as Executive Director, who retires by rotation and being eligible, offers herself for re-appointmentOrdinary100.00% for0.00% against
Against: promoters 0.00% · institutions 0.00% · other public 0.01%
Turnout: all 73.87% · promoters 99.93% · institutions 0.00% · other public 61.04%
- Approval of Material Related Party Transactions to be entered into by the CompanyOrdinary99.99% for0.01% against
Against: promoters 0.00% · institutions 0.00% · other public 0.01%
Turnout: all 22.67% · promoters 0.00% · institutions 0.00% · other public 33.84%
- Approval of Material Related Party Transactions to be entered into by Subsidiaries of the CompanyOrdinary99.99% for0.01% against
Against: promoters 0.00% · institutions 0.00% · other public 0.01%
Turnout: all 22.67% · promoters 0.00% · institutions 0.00% · other public 33.84%
For and against are per cent of the votes cast. Turnout is the votes cast as a per cent of the shares each group holds. Institutions are funds, insurers, banks and foreign investors. An ordinary resolution passes with more than half the votes cast, a special one with at least three quarters.
Investor complaints and compliance
Quarter by quarter.
Investor complaints received and resolved, the company's own count
- Received
- Resolved
Open at the quarter's end
- The board is made up as the listing rules require
- Yes
- The board has a regular chairperson
- Yes
- The company has a risk management committee
- No
- The chair is related to the managing director
- No
- The filing has a part on fines and penalties
- No
- The filing has a part on tax disputes
- No
- There was a cyber security incident in the quarter
- No
The company's own answers in its filing.